// App-Quantinova.ai

P671 : Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands: a retrospective observational study

Researchers

Presenter

  • J R White

Principal Investigators

  • S Din

  • R Ingram

  • S Foley

  • M A Alam

  • R Robinson

  • R Francis

  • E Tucker

  • M Jalal

  • D Elphick

  • E Atallah

  • A Norman

  • M Amin

  • A Sajjad

  • N Heggs

  • S Meadowcroft

  • G Moran

Medical Centers

  • NIHR Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK

  • Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, United Kingdom

  • University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, UK

  • Sherwood Forest Hospitals NHS Foundation Trust, Kings Mill Hospital, Nottingham, UK

  • University Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester, UK

  • Chesterfield Royal Hospital NHS Foundation Trust, Chesterfield

  • United Lincolnshire Hospitals NHS Trust, Lincoln County Hospital, Lincoln, UK

  • Kettering General Hospital NHS Foundation Trust, Kettering, UK

  • Takeda UK Limited, High Wycombe, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Genetic Disorder

  • Gastroenterology (GU)

Disease

  • Inflammatory bowel disease

Biomarkers

  • C reactive protein

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved